The use of monoclonal antibodies in immune-mediated hematologic disorders.
In this article, the evidence on the clinical use of monoclonal antibodies in the treatment of immune-mediated hematologic disorders is described. Insights into pathogenic mechanisms have revealed a major role of both B and T cells. Controlled trials have shown conflicting results, necessitating further research regarding pathogenesis, mechanism of action, and resistance. Although the use of more potent and specific monoclonal antibody therapy, mainly targeting costimulation signals, may improve response rates and long-term outcome, its use should be carefully balanced against potential side effects.
Department of Hematology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Daan.dierickx@uzleuven.be
Daan
D
Dierickx
Emilie
E
Beke
Timothy
T
Devos
André
A
Delannoy
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000276:immunology; D000077552:Basiliximab; D000077561:Daclizumab; D006086:Graft vs Host Disease / Q000188:drug therapy; D006402:Hematologic Diseases / Q000276:immunology* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D000069285:Infliximab; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000074323:Alemtuzumab; D000069283:Rituximab; D000077552:Basiliximab; C481642:eculizumab; D000069285:Infliximab; D000077561:Daclizumab; C079843:inolimomab; C456519:visilizumab